Table 4.
Comparative analysis of AITL patients who received prior auto-HCT vs no prior auto-HCT
| Outcomes | No prior auto-HCT (N = 151) | Prior auto-HCT (N = 98) | p value | ||
|---|---|---|---|---|---|
| N | Prob (95% CI) | N | Prob (95% CI) | ||
| NRM | 151 | 98 | 0.25 | ||
| 1-year | 17 (11–23)% | 22 (14–30)% | 0.33 | ||
| 2-year | 21 (15–28)% | 31 (22–41)% | 0.08 | ||
| 3-year | 22 (16–29)% | 33 (23–43)% | 0.07 | ||
| 4-year | 26 (19–34)% | 36 (26–47)% | 0.11 | ||
| Progression/relapse | 151 | 98 | 0.69 | ||
| 1-year | 16 (11–22)% | 15 (8–22)% | 0.77 | ||
| 2-year | 22 (15–29)% | 16 (9–24)% | 0.23 | ||
| 3-year | 23 (16–30)% | 17 (10–25)% | 0.28 | ||
| 4-year | 24 (17–31)% | 17 (10–25)% | 0.21 | ||
| PFS | 151 | 98 | 0.45 | ||
| 1-year | 68 (60–75)% | 64 (54–73)% | 0.56 | ||
| 2-year | 57 (49–65)% | 53 (43–63)% | 0.53 | ||
| 3-year | 55 (47–64)% | 50 (40–61)% | 0.43 | ||
| 4-year | 50 (42–59)% | 47 (36–57)% | 0.60 | ||
| Overall survival | 151 | 98 | 0.81 | ||
| 1-year | 73 (65–80)% | 74 (65–82)% | 0.81 | ||
| 2-year | 65 (57–72)% | 59 (49–69)% | 0.43 | ||
| 3-year | 61 (53–69)% | 58 (47–68)% | 0.63 | ||
| 4-year | 57 (49–65)% | 54 (44–65)% | 0.70 | ||
Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival, HCT hematopoietic cell transplantation